ACP
FUSN

Acuta Capital Partners’s Fusion Pharmaceuticals Inc. Common Shares FUSN Stock Holding History

Acuta Capital Partners’s Portfolio FUSN Stock Details FUSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-135,000
Closed -$2.36M – 55
2020
Q2 		$2.36M Buy
+135,000
New +$2.35M 0.68% 40

Other funds holding FUSN

JJIJ
Johnson & Johnson Innovation - JJDC New Brunswick, New Jersey $978M AUM 102.17% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Canada Pension Plan Investment Board
Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $155B AUM 29.93% 1-Year Est. Return
TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Acuta Capital Partners's FUSN Position: Q3 2020 in Review

Acuta Capital Partners sold out of Fusion Pharmaceuticals Inc. Common Shares (FUSN) in Q3 2020, closing a stake of 135,000 shares — an estimated $2.36M sold.

Acuta Capital Partners first reported a position in FUSN in Q2 2020 and held it in 1 quarter. The position peaked at $2.36M in Q2 2020. 29 funds tracked by Wall St. Rank hold FUSN as of Q3 2020.

  • Acuta Capital Partners reported no remaining Fusion Pharmaceuticals Inc. Common Shares position as of Q3 2020 after selling out during the quarter.
  • Acuta Capital Partners sold 135,000 Fusion Pharmaceuticals Inc. Common Shares shares in Q3 2020, an estimated $2.36M.
  • Acuta Capital Partners first reported a position in Fusion Pharmaceuticals Inc. Common Shares in Q2 2020 and held it in 1 quarter.
  • Acuta Capital Partners's Fusion Pharmaceuticals Inc. Common Shares position peaked at $2.36M in Q2 2020.
  • 29 funds tracked by Wall St. Rank held Fusion Pharmaceuticals Inc. Common Shares as of Q3 2020.

Based on Acuta Capital Partners's 13F filing for Q3 2020, filed 16 Nov 2020.